Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.
What Glenmark files
- Updates77
- Others38
- Investor Meet32
- Important18
- Dividend/Bonus8
- Board Meeting7
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "Glenmark Expands Global Respiratory Innovation Footprint with RYALTRIS® Launch in Brazil ".
Glenmark's US unit launched Calcium Gluconate Injection USP, strengthening its injectables business. This product enters a US market with estimated annual sales of ~$69.9 million (~₹580 Cr), enhancing its hospital portfolio.
Glenmark Pharma received US approval for its Fluticasone Propionate Nasal Spray, a generic equivalent to Flonase®. This boosts their US respiratory portfolio, targeting a market with $295.2 million in annual sales.
Glenmark Pharma streamlines shareholder access to its FY25-26 Annual Report and 48th AGM Notice. Links and QR codes are being sent to ensure all shareholders can easily review documents for the upcoming virtual Annual General Meeting.
Glenmark USA settled a long-standing antitrust lawsuit with Humana for $15.28 million (~126.8 Cr). Glenmark denies wrongdoing, confirms the amount is provided for, and expects no significant financial impact.